Video

CURE New Issue Alert: 2020 Hematology Special Edition-1

Here are the latest highlights from the first CURE Hematology Special Edition issue for 2020.

Hi, I’m Jessica Skarzynski for CURE Magazine®, your guide to every stage of the cancer experience.

Here’s a look at what’s inside our 2020 Winter Hematology special issue:

For decades the treatment for acute myeloid leukemia remained the same — intensive chemotherapy. But a wave of new targeted therapies in recent years have expanded options for patients while helping them live longer and better lives. We delve into how oncologists are changing up therapy by Making It Personal.

Next, Eyes are on Immunotherapy for patients with relapsed and resistant diffuse large B-cell lymphoma. Our feature story discusses new treatments beyond tried-and-true chemotherapy.

To read these stories and more, visit our publications here and click on the latest CURE cover.

Or, ensure you don’t miss a story when you subscribe to new issue alerts. Visit here for more information.

And, as always, thanks for reading.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.